Bear some medication that is advertised for glucose control and lowering triglyceride also promote MACE reduction. These patients may not be with low-HDL and/or prior acute coronary syndrome but as we are led to believe they still benefit in MACE reduction. Is this not considered as primary prevention with respect to MACE?
Koo